

Reporting of side effects

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this document. You can also report side effects directly (see details below).

Please report side effects to:

The Drug Surveillance Centre
Roche Products (Ireland) Limited
3004 Lake Drive, Citywest,
Naas Road, Dublin 24.
Telephone: (01) 4690700
Email: ireland.drug_surveillance_centre@roche.com

Or report to:

HPRA Pharmacovigilance
Website: www.hpra.ie

Further Information

Talk to your doctor, nurse or pharmacist if you have any questions or concerns.



IE Version 1.2.1

M-IE-00001255

Date of Preparation: July 2022

Date of HPRA Approval: October 2022

Copyright © 2022 by Roche Products (Ireland) Limited.

All rights reserved.

FOR USE IN IRELAND

Important Safety Information for Patients receiving Lunsumio ▼ (mosunetuzumab) Patient Card

- Please carry this card with you at all times while you are receiving Lunsumio (mosunetuzumab).
- Show this card to any healthcare professional involved in your care.

Information for the Patient

Contact your doctor or get emergency help **right away** if you have **any** of these symptoms:

- Fever (38°C or higher)
- Fast or irregular heartbeat
- Chills or shaking chills
- Confusion
- Feeling very tired or weakness
- Difficulty breathing
- Dizziness or light-headedness
- Fainting
- Blurred vision
- Cold or pale clammy skin
- Headache

Experiencing any of these symptoms could be due to **Cytokine Release Syndrome**, which requires immediate evaluation by a doctor.

Cytokine Release Syndrome

- is a group of symptoms caused by small proteins called cytokines, released in your body during inflammation.
- is associated with medicines that stimulate T cells such as Lunsumio (mosunetuzumab).

Information for the Treating Doctor

This patient has received Lunsumio (mosunetuzumab) – **which may cause Cytokine Release Syndrome (CRS)**.

- Evaluate the patient immediately and treat symptoms.
- If CRS is suspected, please refer to section 4.2 of the SmPC for comprehensive instructions on CRS management.
- **Contact the prescribing doctor** as soon as possible – they may need to modify the next infusion of Lunsumio (mosunetuzumab).

Contact Information

Patient's name:

Prescribing Doctor's name:

Prescribing Doctor's phone number:

Date of Lunsumio initiation:

Company contact point

Medical Information at Roche Products (Ireland) Limited by telephone (01 4690700) or email (Ireland.druginfo@roche.com).

Please read this material along with the Package Leaflet supplied with this medicine or also available on www.medicines.ie or www.ema.europa.eu before taking this medicine.